Men with metastatic castration-resistant prostate cancer (mCRPC) derived significantly greater clinical benefit from cabazitaxel vs the androgen receptor-targeted agents (ARTA) abiraterone or enzalutamide, according to the results of the CARD* trial presented at ESMO 2019.
There appears to be no pressing need for men with prostate cancer to undergo radiotherapy immediately after surgery, according to a recent study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019).
Testosterone replacement therapy (TRT) in men with hypogonadism was associated with an increased risk of ischaemic stroke, transient ischaemic attack (TIA), and myocardial infarction (MI), particularly in the first 2 years of use, a study shows.
Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.
The alpha(α) 1A/1D-adrenoceptor blocker tamsulosin was an effective and safe agent for medical expulsion therapy (MET), generating high stone expulsion rates (SER) of distal ureteral calculi measuring <10 mm. However, this success may be at the expense of retrograde ejaculation, a meta-analysis has shown.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.